Механизмы фиброзообразования при хронических заболеваниях печени и возможности антифибротической терапии

1. Глушенков Д.В., Павлов Ч.С., Золотаревский В.Б. и др. Чувствительность и специфичность фибротеста у больных ХГС/ХГВ на разных стадиях фиброза печени. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2008; 
1 (Прил. 31): 25.
2. Матвеев А.В. Гепатопротекторы. Анализ международных исследований по препаратам группы лекарств для печени. 2013.
3. Северов М.В. Обратим ли цирроз печени? Клин. гепатология. 2006; 3: 3–9.
4. Яковенко Э.П., Яковенко А.В., Иванов А.Н. и др. Фиброз печени: механизмы развития и вопросы терапии.. Фарматека. 2011; 12: 1–6.
5. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160–74.
6. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315–34.
7. Al-Mohri H, Murphy T, Lu Y et al. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 4 (44): 463.
8. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 3 (4): 575–96.
9. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis 2001; 21: 437–51.
10. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46: 443–6.
11. Bhatt RS, Bubley GJ. Clin Cancer Res 2008; 14: 7581–82.
12. Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.. Gastroenterology 2009; 137 (1): 390–1.
13. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3–20.
14. Cai WM, Tao J, Weng HL et al. Study on the influence factors of the serum fibrosis markers. Zhonghua Gan Zang Bing Za Zhi 2003; 1 (11): 23–5.
15. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis..Hepatology. 2004; 39: 273–8.
16. Chen-Hua Liu, Shih-Jer Hsu, Jou-Wei Lin et al. Неинвазивная диагностика фиброза печени при хроническом гепатите С с помощью допплерографии по индексу пульсации селезеночной артерии. Клин. гастроэнтерол. и гепатол. Русское издание. 2008; 8: 101–7.
17. Dehmlow С, Erhard J, Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of Silibinin. Life Sci 1996; 58: 749–54, 
18. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647–54.
19. Fabris C, Smirne C, Toniutto P et al. Assessment of liver fibrosis progressi-on in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006; 4 (39): 339–43.
20. Ferenci et al. J Hepatol 1989; 9: 105–13.
21. Forms X. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986–92.
22. Freedman ND, Curto TM, Morishima C et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Alimentary Pharmacology and Therapeutics (Epub before print). doi: 10.1111/j.1365-2036.2010.04503.
23. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol 2003; 38.
24. Fuchs et al. Arzneim.-Forsch. Drug Res 1997; 47: 1383–87.
25.  Fаrkkilа M, Rautiainen H, Kаrkkаinen P et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on urso-deoxycholic acid therapy. Liver Int 2008; 6 (28); 761–3.
26. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis 2001; 21: 311–35.
27. Giannini EG, Zaman A, Ceppa P et al. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol 2008; 2 (42): 219–20.
28. Gindy I, Rahman AT, Alim MA et al. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol 2003; 1: 27–35.
29. Gressner AM, Weiskirchen R, Breitkopf et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793–d807.
30. Hartley JL, Brown RM, Tybulewicz A et al. Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease. J Pediatr Gastroenterol Nutr 2006; 2 (43): 217–21.
31. Higuchi H., Gores, G.J. Mechanisms of liver injury: an overview..Curr Mol Med 2003; 3: 483–90.
32. Housset C, Guеchot J. Hepatic fibrosis: physiopathology and biological diagnosis. Pathol Biol (Paris) 1999; 9 (47): 886–94.
33. Huang W, Gong FY. Diagnostic value of serum biochemical markers for liver fibrosis in patients with hepatitis B virus. Di Yi Jun Yi Da Xue Xue Bao 2002; 11 (22): 1034–6.
34. Imbert-Bismut F. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357 (9252): 1069–75.
35. Imperiale TF, Said AT, Cummings OW et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2001; 3 (96): 918–9.
36. Jia et al. Hepatology 1998; 28: 546A.
37. Keyur Patel, David R.Nelson, Don C.Rockey et al. Соотношение результатов FIBROSpect II с гистологической и морфометрической оценкой фиброза печени при хроническом гепатите С. Клин. гастроэнтерол. и гепатол. Русское издание. 2008; 8: 117–23.
38. Ladas EJ, Kroll DJ, Oberlies NH et at. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010; 116 (2): 506–13.
39. Lindquist JN, Parsons CJ, Stefanovic B, Brenner DA. Regulation of alpha1 (I) collagen messenger RNA decay by interactions with alphaCP at the 3'-untranslated region. J Biol Chem 2004; 279: 23822–9.
40. Mourelle et al. Fundam. Clin Pharmacol 1989; 3: 183–91.
41. Nyblom H, Bjоrnsson E, Sim-rеn M et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006; 7 (26): 840–5.
42. Pares A, Caballeria J, Bruguera M et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2: 33–42.
43. Park GJ, Lin BP, Ngu MC et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 4 (15): 386–90.
44. Park JH, Park CK, Kim ES et al. The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients. Taehan Kan Hakhoe Chi 2003; 2 (9): 79–88.
45. Paveс S, Svirtlih N, Simonoviс J et al. The importance of aminotransferases and platelets count in non-invasive evaluation stages of chronic hepatitis C. Srp Arh Celok Lek 2005; 5–6 (133): 262–5.
46. Payer BA, Reiberger T, Rutter K. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV–HCV coinfected patient. J Clin Virol 2010; 49: 131–3.
47. Ramasamy K, Agarwal R. Cancer Lett 2008; 269 (2): 352–62.
48. Rockey DC. Clin Gastroenterol Hepatol 2005; 3: 95–107.
49. Rosenberg W., Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–13.
50. Santos VN, Leite-Mоr MM, Kondo M et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. J Med Biol Res 2005; 
5 (38): 747–53.
51. Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 2 (46): 307–14.
52. Schuppan D, Pinzani M. Anti-fibrotic therapy: Lost in translation? J Hepatology 2012; 56 (Suppl. 1): S56–S74.
53. Schuppan Z. Allg Med 1998; 74: 577–84.
54. Seeff LB, Curto TM, Szabo G et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial Hepatology 2008; 47: 605–12.
55. Sheth SG, Flamm SL, Gordon FD et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 1 (93): 44–8.
56. Snyder N, Gajula L, Xiao SY et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006; 6 (40): 535–42.
57. Alan R.. Plant flavonoids in biology and medicine. Liss Sonnenbichler Zetl 1986; 319–31.
58. Velussi et al. J Hepatol 1997; 26: 871–9.
59. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26.

Е.В.Голованова

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России